Program Chair
Jon T. Giles, MD, MPH
Associate Professor of Medicine
Division of Rheumatology
Columbia University, College of Physicians & Surgeons
New York, NY
Faculty
Joerg Ermann, MD
Assistant Professor of Medicine
Harvard University Medical School
Associate Professor
Brigham and Women’s Hospital
Boston, MA
PROGRAM OVERVIEW
This TeleECHO series has been designed for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with rheumatoid arthritis (RA), to better interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAK inhibitors (JAKi) with different mechanisms of action in patients with moderate-to-severe RA. This series will help health professionals incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice, and it also supports patient-centered multidisciplinary team-based approaches to the management of those patients with moderate-to-severe RA.
TARGET AUDIENCE
This activity is intended for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with RA.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAKi with different mechanisms of action in patients with moderate-to-severe RA
- Incorporate new evidence-based management recommendations on the use of JAKi for patients with moderateto-severe RA into clinical practice
- Support patient-centered multidisciplinary team-based approaches to the management of those with moderateto-severe RA
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group will designate each enduring meeting and simulcast for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live-virtual activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with rheumatoid arthritis.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| Faculty Member | Disclosures |
| Dr. Giles | Discloses that he has received consulting fees from AbbVie, Pfizer, Bristol Myers Squibb, UCB, Eli Lilly, and Gilead. He has also provided contracted research to Pfizer. |
| Dr. Ermann | Discloses that he has worked as a Consultant on Scientific Advisory Boards for Eli Lilly, Pfizer and UCB. He has also received research grants from AbbVie, Novartis, UCB and Pfizer. |
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- James Seternus, DO, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 03, 2022
EXPIRATION DATE: October 03, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
